List – 65 Drug Patents that are Expiring in 2025
Recently, we published a list of drug patents expiring in 2023 and 2024. The list saw tremendous interest from people in the generic pharmaceutical industry. And why not?
With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible. We totally get it. And keeping that very thought in mind, we collated a list of 65 drugs that are going off-patent in 2025. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the drug most profitable to develop a generic version.
Loved the idea and the list? Thank us later in the comments section. Now onto the list.
The article has a list of drug patents expiring in 2025. If you want to get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.
Drug Patents Expiring in 2025
Xalkori
Crizotinib
Crizotinib
Sales:
$524 Million (2018)
$524 Million (2018)
Patents | Expiration Date |
---|---|
US8785632 | March 01, 2025 |
US7230098 | August 26, 2025 |
US7858643 | October 8, 2029 |
US8217057 | November 6, 2029 |
Dosage: Capsule; Oral
Company: Pfizer
Ingredients: Crizotinib
Treatment: Non-Small Cell Lung Carcinoma
Omegaven
Fish Oil Triglycerides
Fish Oil Triglycerides
Sales:
–
–
Patents | Expiration Date |
---|---|
US9566260 | July 11, 2025 |
US9629821 | July 11, 2025 |
US10350186 | November 05, 2024 |
Dosage: Emulsion; Intravenous
Company: Fresenius Kabi USA LLC
Ingredients: Fish Oil Triglycerides
Treatment: Parenteral Nutrition-Associated Cholestasis (PNAC)
Yupelri
Revefenacin
Revefenacin
Sales:
$3.3 Million (Q4, 2018)
$3.3 Million (Q4, 2018)
Patents | Expiration Date |
---|---|
US7491736 | March 10, 2025 |
US7521041 | March 10, 2025 |
US7550595 | March 10, 2025 |
US7585879 | March 10, 2025 |
US7910608 | March 10, 2025 |
US7288657 | December 23, 2025 |
US10550081 | July 14, 2030 |
US9765028 | July 14, 2030 |
US8541451 | August 25, 2031 |
Dosage: Solution; Inhalation
Company: Mylan Ireland Ltd
Ingredients: Revefenacin
Treatment: Chronic Obstructive Pulmonary Disease
Sprycel
Dasatinib
Dasatinib
Sales:
$2 Billion (2018)
$2 Billion (2018)
Patents | Expiration Date |
---|---|
US8680103 | February 04, 2025 |
Dosage: Tablet; Oral
Company: Bristol Myers Squibb Co
Ingredients: Dasatinib
Treatment: Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL)
Bosulif
Bosutinib Monohydrate
Bosutinib Monohydrate
Sales:
$477 Million (2019)
$477 Million (2019)
Patents | Expiration Date |
---|---|
US7417148 | December 11, 2025 |
US7767678 | November 23, 2026 |
US7919625 | December 11, 2025 |
Dosage: Tablet; Oral
Company: PF Prism CV
Ingredients: Bosutinib Monohydrate
Treatment: Chronic Phase Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
Cresemba
Isavuconazonium Sulfate
Isavuconazonium Sulfate
Sales:
$180 Million (Jul 2018 – Jun 2019)
$180 Million (Jul 2018 – Jun 2019)
Patents | Expiration Date |
---|---|
US6812238 | October 31, 2025 |
Dosage: Capsule; Oral
Company: Astellas Pharma US Inc
Ingredients: Isavuconazonium Sulfate
Treatment: Invasive Aspergillosis And Mucormycosis
Antara
Fenofibrate
Fenofibrate
Sales:
$70 Million (2008)
$70 Million (2008)
Patents | Expiration Date |
---|---|
US8026281 | April 22, 2025 |
Dosage: Capsule; Oral
Company: Lupin Inc
Ingredients: Fenofibrate
Treatment: High Cholesterol and Triglycerides (fatty acids) in Blood
Lysteda
Tranexamic Acid
Tranexamic Acid
Sales:
$25 Million (2012)
$25 Million (2012)
Patents | Expiration Date |
---|---|
US7947739 | March 04, 2025 |
US8022106 | March 04, 2025 |
US8273795 | March 04, 2025 |
US8487005 | March 04, 2025 |
US8791160 | March 04, 2025 |
US8809394 | March 04, 2025 |
US8957113 | March 04, 2025 |
US9060939 | March 04, 2025 |
Dosage: Tablet; Oral
Company: Amring Pharmaceuticals Inc
Ingredients: Tranexamic Acid
Treatment: Cyclic Heavy Menstrual Bleeding
Bepreve
Bepotastine Besilate
Bepotastine Besilate
Sales:
$160.3 Million (2011)
$160.3 Million (2011)
Patents | Expiration Date |
---|---|
US8784789 | January 13, 2025 |
US8877168 | July 30, 2023 |
Dosage: Solution/Drops; Ophthalmic
Company: Bausch And Lomb Inc
Ingredients: Bepotastine Besilate
Treatment: Itching of the Eyes due to Allergies
Sancuso
Granisetron
Granisetron
Sales:
$20 – $25 Million
$20 – $25 Million
Patents | Expiration Date |
---|---|
US7608282 | January 22, 2025 |
Dosage: Film, Extended Release; Transdermal
Company: Kyowa Kirin Inc
Ingredients: Granisetron
Treatment: Nausea and Vomiting Caused by Cancer Chemotherapy
Nucynta
Tapentadol Hydrochloride
Tapentadol Hydrochloride
Sales:
$46.8 Million (2019)
$46.8 Million (2019)
Patents | Expiration Date |
---|---|
US7994364 | June 27, 2025 |
Dosage: Tablet; Oral
Company: Collegium Pharmaceuticals Inc
Ingredients: Tapentadol Hydrochloride
Treatment: Moderate to Severe Pain
Nexlizet
Bempedoic Acid, Ezetimibe
Bempedoic Acid, Ezetimibe
Sales:
–
–
Patents | Expiration Date |
---|---|
US7335799 | December 03, 2025 |
Dosage: Tablet; Oral
Company: Esperion Therapeutics Inc
Ingredients: Bempedoic Acid, Ezetimibe
Treatment: Reduce the Amount of Cholesterol and other Fatty Substances in Blood
Vyzulta
Latanoprostene Bunod
Latanoprostene Bunod
Sales:
–
–
Patents | Expiration Date |
---|---|
US8058467 | January 5, 2025 |
US7910767 | January 5, 2025 |
US7273946 | October 3, 2025 |
Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: LATANOPROSTENE BUNOD
Treatment: Intraocular Pressure in Patients with Open-angle Glaucoma or Ocular Hypertension
Trilipix
Fenofibrate
Fenofibrate
Sales:
–
–
Patents | Expiration Date |
---|---|
US7259186 | January 7, 2025 |
Dosage: Oral
Company: AbbVie Inc
Ingredients: CHOLINE FENOFIBRATE
Treatment: Abnormal Blood Lipid Levels
Duaklir
Aclidinium bromide/formoterol
Aclidinium bromide/formoterol
Sales:
–
–
Patents | Expiration Date |
---|---|
USRE46417 | February 10, 2025 |
Dosage: Inhalation
Company: ALMIRALL, S.A
Ingredients: ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)
Arcapta
Indacaterol
Indacaterol
Sales:
–
–
Patents | Expiration Date |
---|---|
US6878721 | February 25, 2025 |
Dosage: Inhalation
Company: Novartis
Ingredients: INDACATEROL MALEATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)
Rukobia
Fostemsavir
Fostemsavir
Sales:
–
–
Patents | Expiration Date |
---|---|
US8461333 | February 25, 2025 |
US7745625 | November 19, 2027 |
Dosage: Oral
Company: ViiV Healthcare
Ingredients: FOSTEMSAVIR TROMETHAMINE
Treatment: HIV/AIDS
Incivek
Telaprevir
Telaprevir
Sales:
–
–
Patents | Expiration Date |
---|---|
US7820671 | February 25, 2025 |
Dosage: Oral
Company: Johnson & Johnson
Ingredients: TELAPREVIR
Treatment: Hepatitis C
Viberzi
Eluxadoline
Eluxadoline
Sales:
–
–
Patents | Expiration Date |
---|---|
US10213415 | March 14, 2025 |
US8609709 | March 14, 2025 |
US7786158 | March 14, 2025 |
US9115091 | July 7, 2028 |
US8691860 | July 7, 2028 |
US7741356 | May 27, 2029 |
Dosage: Oral
Company: Allergan
Ingredients: ELUXADOLINE
Treatment: Diarrhea and Abdominal Pain
Glucophage
Metformin
Metformin
Sales:
–
–
Patents | Expiration Date |
---|---|
US7780987 | March 23, 2025 |
Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes
Roxicodone
Oxycodone
Oxycodone
Sales:
–
–
Patents | Expiration Date |
---|---|
US10696684 | March 30, 2025 |
US10407434 | March 30, 2025 |
US9522919 | March 30, 2025 |
US9073933 | March 30, 2025 |
Dosage: Oral, Sublingual, Intramuscular, Intravenous, Intranasal, Subcutaneous, Transdermal, Rectal, Epidural
Company: Xanodyne Pharmaceuticals
Ingredients: OXYCODONE HYDROCHLORIDE
Treatment: Moderate to Severe Pain
Tegsedi
Inotersen
Inotersen
Sales:
–
–
Patents | Expiration Date |
---|---|
US8101743 | April 1, 2025 |
US9061044 | April 29, 2031 |
Dosage: Subcutaneous injection
Company: Akcea Therapeutics, Inc.
Ingredients: INOTERSEN SODIUM
Treatment: Nerve Damage in adults with Hereditary transthyretin-mediated Amyloidosis
Reyvow
Lasmiditan
Lasmiditan
Sales:
–
–
Patents | Expiration Date |
---|---|
US7423050 | April 6, 2025 |
US11053214 | December 5, 2037 |
Dosage: Oral, Intravenous
Company: Eli Lilly and Company
Ingredients: LASMIDITAN SUCCINATE
Treatment: Migraine with or without Aura
Kyprolis
Carfilzomib
Carfilzomib
Sales:
$1.06 Billion (2020)
$1.06 Billion (2020)
Patents | Expiration Date |
---|---|
US8207125 | April 14, 2025 |
US7232818 | April 14, 2025 |
US8207297 | April 14, 2025 |
US7417042 | July 20, 2026 |
Dosage: Intravenous
Company: Amgen Inc.
Ingredients: CARFILZOMIB
Treatment: Relapsed or Refractory Multiple Myeloma
Biktarvy
Bictegravir/emtricitabine/tenofovir alafenamide
Bictegravir/emtricitabine/tenofovir alafenamide
Sales:
–
–
Patents | Expiration Date |
---|---|
US7390791 | April 17, 2025 |
US9296769 | August 15, 2032 |
US8754065 | August 15, 2032 |
US9216996 | December 19, 2033 |
US9732092 | December 19, 2033 |
US9708342 | June 19, 2035 |
Dosage: Oral
Company: Gilead Sciences
Ingredients: BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Treatment: HIV/AIDS
Stendra
Avanafil
Avanafil
Sales:
–
–
Patents | Expiration Date |
---|---|
US6656935 | April 27, 2025 |
Dosage: Oral
Company: Vivus Inc.
Ingredients: AVANAFIL
Treatment: Erectile Dysfunction
Inlyta
Axitinib
Axitinib
Sales:
$93 Million (2020)
$93 Million (2020)
Patents | Expiration Date |
---|---|
US6534524 | April 29, 2025 |
US8791140 | December 14, 2030 |
Dosage: Oral
Company: Pfizer
Ingredients: AXITINIB
Treatment: Renal Cell Carcinoma
Camptosar
Irinotecan
Irinotecan
Sales:
–
–
Patents | Expiration Date |
---|---|
US9782349 | May 2, 2025 |
US9724303 | May 2, 2025 |
US8992970 | May 2, 2025 |
US10722508 | May 2, 2025 |
US8329213 | January 6, 2027 |
US8147867 | August 29, 2028 |
Dosage: Intravenous
Company: Pfizer
Ingredients: IRINOTECAN HYDROCHLORIDE
Treatment: Colon Cancer and Small Cell Lung Cancer
Jentadueto
Linagliptin/metformin hydrochloride
Linagliptin/metformin hydrochloride
Sales:
–
–
Patents | Expiration Date |
---|---|
US7407955 | May 2, 2025 |
Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Treatment: High Blood Sugar Levels caused by Type 2 Diabetes
Pexeva
Paroxetine mesylate
Paroxetine mesylate
Sales:
–
–
Patents | Expiration Date |
---|---|
US7598271 | May 4, 2025 |
US8946251 | August 4, 2026 |
US8658663 | April 6, 2029 |
Dosage: Oral
Company: Sebela Pharmaceutical
Ingredients: PAROXETINE MESYLATE
Treatment: Symptoms of Menopause
Doptelet
Avatrombopag
Avatrombopag
Sales:
–
–
Patents | Expiration Date |
---|---|
US7638536 | May 5, 2025 |
Dosage: Oral
Company: AkaRx, Inc.
Ingredients: AVATROMBOPAG MALEATE
Treatment: Thrombocytopenia Associated with Chronic Liver Disease
Lymphoseek
Technetium Tc 99m tilmanocept
Technetium Tc 99m tilmanocept
Sales:
–
–
Patents | Expiration Date |
---|---|
US6409990 | May 12, 2025 |
US9439985 | September 27, 2033 |
Dosage: Subcutaneous injection
Company: Navidea Biopharmaceuticals
Ingredients: TECHNETIUM TC-99M TILMANOCEPT
Treatment: Identify Sentinel Lymph Nodes
Olysio
Simeprevir
Simeprevir
Sales:
–
–
Patents | Expiration Date |
---|---|
US7671032 | May 19, 2025 |
US8349869 | July 28, 2026 |
US8754106 | July 28, 2026 |
US8741926 | July 28, 2026 |
US9040562 | July 28, 2026 |
US9856265 | July 28, 2026 |
US8148399 | September 5, 2029 |
Dosage: Oral
Company: Johnson & Johnson
Ingredients: SIMEPREVIR SODIUM
Treatment: Hepatitis C
Edarbi
Azilsartan
Azilsartan
Sales:
–
–
Patents | Expiration Date |
---|---|
US7157584 | May 22, 2025 |
Dosage: Oral
Company: Takeda Pharmaceutical
Ingredients: AZILSARTAN KAMEDOXOMIL
Treatment: Hypertension
Onpattro
Patisiran
Patisiran
Sales:
–
–
Patents | Expiration Date |
---|---|
US8334373 | May 27, 2025 |
US8168775 | October 20, 2029 |
US10240152 | October 20, 2029 |
US11079379 | August 27, 2035 |
Dosage: Intravenous
Company: Alnylam Pharmaceuticals
Ingredients: PATISIRAN SODIUM
Treatment: Polyneuropathy in People with Hereditary transthyretin-mediated Amyloidosis
Diprivan
Propofol
Propofol
Sales:
–
–
Patents | Expiration Date |
---|---|
US8476010 | June 1, 2025 |
Dosage: Intravenous
Company: Fresenius Kabi
Ingredients: PROPOFOL
Treatment: Used to help Patients Relax before and during General Anesthesia for Surgery
Kazano
Alogliptin/metformin
Alogliptin/metformin
Sales:
–
–
Patents | Expiration Date |
---|---|
US8288539 | June 24, 2025 |
US7807689 | June 27, 2028 |
Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE
Treatment: Blood Sugar Control in Adults with Type 2 Diabetes
Amondys 45
Casimersen
Casimersen
Sales:
–
–
Patents | Expiration Date |
---|---|
US9447415 | June 28, 2025 |
US8524880 | April 2, 2026 |
US10287586 | November 12, 2030 |
US9228187 | November 12, 2030 |
Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: CASIMERSEN
Treatment: Duchenne Muscular Dystrophy (DMD)
Exondys 51
Eteplirsen
Eteplirsen
Sales:
–
–
Patents | Expiration Date |
---|---|
US10781451 | June 28, 2025 |
US9018368 | June 28, 2025 |
US9243245 | October 27, 2028 |
Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: ETEPLIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)
Vyondys 53
Golodirsen
Golodirsen
Sales:
–
–
Patents | Expiration Date |
---|---|
US10227590 | June 28, 2025 |
US9994851 | June 28, 2025 |
US9024007 | June 28, 2025 |
US10968450 | June 28, 2025 |
US10421966 | June 28, 2025 |
Dosage: Intravenous
Company: Sarepta Therapeutics, Inc.
Ingredients: GOLODIRSEN
Treatment: Duchenne Muscular Dystrophy (DMD)
Vyleesi
Bremelanotide
Bremelanotide
Sales:
–
–
Patents | Expiration Date |
---|---|
US6794489 | June 28, 2025 |
Dosage: Subcutaneous
Company: Palatin Technologies
Ingredients: BREMELANOTIDE ACETATE
Treatment: Low Sexual Desire in Women
Zydelig
Idelalisib
Idelalisib
Sales:
–
–
Patents | Expiration Date |
---|---|
USRE44638 | August 5, 2025 |
US8865730 | March 5, 2033 |
US10730879 | March 5, 2033 |
US9469643 | September 2, 2033 |
Dosage: Oral
Company: Gilead Sciences
Ingredients: IDELALISIB
Treatment: Blood Cancer
Duzallo
Lesinurad/Allopurinol
Lesinurad/Allopurinol
Sales:
–
–
Patents | Expiration Date |
---|---|
US8003681 | August 25, 2025 |
US8546436 | February 29, 2032 |
Dosage: Oral
Company: AstraZeneca
Ingredients: ALLOPURINOL; LESINURAD
Treatment: Gout
Prolensa
Bromfenac
Bromfenac
Sales:
–
–
Patents | Expiration Date |
---|---|
US8129431 | September 11, 2025 |
Dosage: Eye Drops
Company: Bausch & Lomb
Ingredients: BROMFENAC SODIUM
Treatment: Ocular Inflammation and Pain after Cataract Surgery
Nuplazid
Pimavanserin
Pimavanserin
Sales:
–
–
Patents | Expiration Date |
---|---|
US7923564 | September 26, 2025 |
US7732615 | June 3, 2028 |
US7601740 | April 29, 2030 |
Dosage: Oral
Company: Acadia Pharmaceuticals
Ingredients: PIMAVANSERIN TARTRATE
Treatment: Parkinson’s disease psychosis
Baxdela
Delafloxacin
Delafloxacin
Sales:
–
–
Patents | Expiration Date |
---|---|
US9539250 | October 7, 2025 |
US8273892 | August 6, 2026 |
US7728143 | November 20, 2027 |
US8871938 | September 23, 2029 |
USRE46617 | December 28, 2029 |
Dosage: Oral, Intravenous
Company: Melinta Therapeutics
Ingredients: DELAFLOXACIN MEGLUMINE
Treatment: Acute Bacterial Skin and Skin Structure Infections
Lenvima
Lenvatinib
Lenvatinib
Sales:
–
–
Patents | Expiration Date |
---|---|
US7253286 | October 24, 2025 |
US7612208 | September 19, 2026 |
US11186547 | August 26, 2035 |
US10407393 | August 26, 2035 |
US10259791 | August 26, 2035 |
Dosage: Oral
Company: Eisai Inc
Ingredients: LENVATINIB MESYLATE
Treatment: Thyroid Cancer
Cresemba
Isavuconazole
Isavuconazole
Sales:
–
–
Patents | Expiration Date |
---|---|
US6812238 | October 31, 2025 |
Dosage: Oral, Intravenous
Company: Astellas Pharma
Ingredients: ISAVUCONAZONIUM SULFATE
Treatment: Aspergillosis and Mucormycosis
Lybalvi
Olanzapine/samidorphan
Olanzapine/samidorphan
Sales:
–
–
Patents | Expiration Date |
---|---|
US7262298 | November 23, 2025 |
US9119848 | August 30, 2031 |
Dosage: Oral
Company: Alkermes, Inc
Ingredients: OLANZAPINE; SAMIDORPHAN L-MALATE
Treatment: Schizophrenia and Bipolar Disorder
Opsumit
Macitentan
Macitentan
Sales:
–
–
Patents | Expiration Date |
---|---|
US7094781 | December 5, 2025 |
Dosage: Oral
Company: Actelion Pharmaceuticals
Ingredients: MACITENTAN
Treatment: Pulmonary Arterial Hypertension
Latuda
Lurasidone
Lurasidone
Sales:
–
–
Patents | Expiration Date |
---|---|
USRE45573 | December 23, 2025 |
Dosage: Oral
Company: Sunovion Pharmaceuticals
Ingredients: LURASIDONE HYDROCHLORIDE
Treatment: Schizophrenia and Bipolar Disorder
Klisyri
Tirbanibulin
Tirbanibulin
Sales:
–
–
Patents | Expiration Date |
---|---|
US8980890 | December 28, 2025 |
US8236799 | December 28, 2025 |
US7300931 | February 6, 2026 |
US7851470 | February 2, 2029 |
US10669236 | September 7, 2038 |
Dosage: Topical
Company: Almirall, LLC.
Ingredients: TIRBANIBULIN
Treatment: Actinic Keratosis
Signifor
Pasireotide
Pasireotide
Sales:
–
–
Patents | Expiration Date |
---|---|
US8299209 | December 27, 2025 |
US7473761 | December 14, 2026 |
Dosage: Subcutaneous Injection, Intramuscular Injection
Company: Recordati Rare Diseases Inc.
Ingredients: PASIREOTIDE DIASPARTATE
Treatment: Cushing’s Disease
Conclusion
As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version.
With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.
Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team